Prognostic factors in stage I-III adrenocortical cancer (ACC): Data of 230 patients from the ICARO_GETHI/SEEN registry

#3562

Introduction: The scientific evidence on adjuvant treatment of adrenocortical carcinoma (ACC) is scarce and based on a retrospective Italian-German series.

Aim(s): The aim was to describe prognostic factors and analyse the role of mitotane as adjuvant treatment in patients with resected stage I-III ACC.

Materials and methods: Cases were from the national and multicenter (28 hospitals) ICARO_GETTHI/SEEN registry. Disease-free survival (DFS) and overall survival (OS) were assessed with Kaplan-Meier and prognostic factors were analysed with Cox regression.

Conference:

Presenting Author: Jimenez-Fonseca P

Authors: Ballester I, Álvarez-Escolá C, Valdes N, Hernando J, Picon M,

Keywords: Adrenocortical cancer, Adjuvant treatment, Mitotane, Prognosis, Survival,